Literature DB >> 31115638

Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617.

Mike M Sathekge1,2, Frank Bruchertseifer3, Ismaheel O Lawal4,5, Mariza Vorster4,5, Otto Knoesen6, Thabo Lengana4,5, Tebatso G Boshomane4,5, Kgomotso K Mokoala4,5, Alfred Morgenstern4,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31115638     DOI： 10.1007/s00259-019-04354-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  5 in total

1.  225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.

Authors:  Clemens Kratochwil; Frank Bruchertseifer; Frederik L Giesel; Mirjam Weis; Frederik A Verburg; Felix Mottaghy; Klaus Kopka; Christos Apostolidis; Uwe Haberkorn; Alfred Morgenstern
Journal:  J Nucl Med       Date:  2016-07-07       Impact factor: 10.057

2.  Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.

Authors:  Xiao Wei; Carl Schlenkhoff; Bettina Schwarz; Markus Essler; Hojjat Ahmadzadehfar
Journal:  Clin Nucl Med       Date:  2017-09       Impact factor: 7.794

3.  Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control.

Authors:  Clemens Kratochwil; Frank Bruchertseifer; Hendrik Rathke; Markus Hohenfellner; Frederik L Giesel; Uwe Haberkorn; Alfred Morgenstern
Journal:  J Nucl Med       Date:  2018-01-11       Impact factor: 10.057

4.  Brain metastasis from prostate carcinoma: The M. D. Anderson Cancer Center experience.

Authors:  Ivo W Tremont-Lukats; George Bobustuc; George K Lagos; Konstantinos Lolas; Athanassios P Kyritsis; Vinay K Puduvalli
Journal:  Cancer       Date:  2003-07-15       Impact factor: 6.860

5.  225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.

Authors:  Mike Sathekge; Frank Bruchertseifer; Otto Knoesen; Florette Reyneke; Ismaheel Lawal; Thabo Lengana; Cindy Davis; Johncy Mahapane; Ceceila Corbett; Mariza Vorster; Alfred Morgenstern
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-19       Impact factor: 9.236
  5 in total
  8 in total

1.  Ga-68 PSMA PET/CT in recurrent high-grade gliomas: evaluating PSMA expression in vivo.

Authors:  Arunav Kumar; Sreedharan Thankarajan ArunRaj; Khush Bhullar; K P Haresh; Subhash Gupta; Sanjana Ballal; Madhav Yadav; Manmohan Singh; Nishikant Avinash Damle; Ajay Garg; Madhavi Tripathi; Chandrasekhar Bal
Journal:  Neuroradiology       Date:  2021-10-14       Impact factor: 2.804

2.  Advances in PSMA theranostics.

Authors:  Thomas M Jeitner; John W Babich; James M Kelly
Journal:  Transl Oncol       Date:  2022-05-18       Impact factor: 4.803

3.  Preclinical Targeted α- and β--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies.

Authors:  Janik Puttemans; Yana Dekempeneer; Jos L Eersels; Heleen Hanssens; Pieterjan Debie; Marleen Keyaerts; Albert D Windhorst; Frank van der Aa; Quentin Lecocq; Karine Breckpot; Alfred Morgenstern; Frank Bruchertseifer; Tony Lahoutte; Nick Devoogdt; Matthias D'Huyvetter
Journal:  Cancers (Basel)       Date:  2020-04-21       Impact factor: 6.639

Review 4.  Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors.

Authors:  Brittany M Stopa; James Crowley; Csaba Juhász; Cara M Rogers; Mark R Witcher; Jackson W Kiser
Journal:  Mol Imaging       Date:  2022-04-15       Impact factor: 3.250

Review 5.  Supply and Clinical Application of Actinium-225 and Bismuth-213.

Authors:  Alfred Morgenstern; Christos Apostolidis; Frank Bruchertseifer
Journal:  Semin Nucl Med       Date:  2020-02-21       Impact factor: 4.446

Review 6.  Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen.

Authors:  Masayuki Inubushi; Hiroyuki Miura; Ichiei Kuji; Kimiteru Ito; Ryogo Minamimoto
Journal:  Ann Nucl Med       Date:  2020-11-11       Impact factor: 2.668

Review 7.  Radiolabeled PSMA Inhibitors.

Authors:  Oliver C Neels; Klaus Kopka; Christos Liolios; Ali Afshar-Oromieh
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

Review 8.  Global experience with PSMA-based alpha therapy in prostate cancer.

Authors:  Mike M Sathekge; Frank Bruchertseifer; Mariza Vorster; Alfred Morgenstern; Ismaheel O Lawal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-26       Impact factor: 9.236
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.